Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma

Tatsuo Kuroda, Nobuyuki Morikawa, Kentaro Matsuoka, Akihiro Fujino, Toshiro Honna, Atsuko Nakagawa, Masaaki Kumagai, Hidekazu Masaki, Morihiro Saeki

研究成果: Article

13 引用 (Scopus)

抄録

Purpose: The aim of this study was to study the prognostic significance of circulating tumor cells (CTC) and the appropriate indications for aggressive surgery in advanced neuroblastoma. Materials and Methods: Micrometastasis was sequentially explored using our reverse transcriptase-polymerase chain reaction method in 29 neuroblastoma patients (International Neuroblastoma Staging System stage 4, n = 24; stage 3, n = 5) who treated at our department with the united chemotherapeutic regimen since 1991. Their medical records and detection of CTC and/or the bone marrow micrometastasis were retrospectively reviewed then analyzed statistically. Results: The overall survival rate was 58.6% (17/29). Circulating tumor cells were detected in 55.6% of the stage 4 patients, and all deaths were related to systemic metastases in the CTC-positive patients. The detection of CTC scarcely associated with MYCN amplification. In the patients showing MYCN amplification but no CTC, all deaths were related to local relapse or chemotherapy-associated complications. The survival rate was not significantly different between the patients with and without MYCN amplification (56.8% vs 52.7%). However, it was significantly lower in the patients with CTC and/or persistent bone marrow micrometastasis compared to those without detectable micrometastasis (33.8% vs 87.5%; P < .05). Conclusions: The presence of CTC and/or persistent micrometastasis may indicate a significantly high risk, regardless of MYCN amplification. Patients with MYCN amplification but no micrometastasis would be most benefited by highly intensive surgery.

元の言語English
ページ(範囲)2182-2185
ページ数4
ジャーナルJournal of Pediatric Surgery
43
発行部数12
DOI
出版物ステータスPublished - 2008 12
外部発表Yes

Fingerprint

Circulating Neoplastic Cells
Neoplasm Micrometastasis
Neuroblastoma
Bone Marrow
Survival Rate
Reverse Transcriptase Polymerase Chain Reaction
Medical Records
Cell Death
Neoplasm Metastasis
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

これを引用

Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. / Kuroda, Tatsuo; Morikawa, Nobuyuki; Matsuoka, Kentaro; Fujino, Akihiro; Honna, Toshiro; Nakagawa, Atsuko; Kumagai, Masaaki; Masaki, Hidekazu; Saeki, Morihiro.

:: Journal of Pediatric Surgery, 巻 43, 番号 12, 12.2008, p. 2182-2185.

研究成果: Article

Kuroda, T, Morikawa, N, Matsuoka, K, Fujino, A, Honna, T, Nakagawa, A, Kumagai, M, Masaki, H & Saeki, M 2008, 'Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma', Journal of Pediatric Surgery, 巻. 43, 番号 12, pp. 2182-2185. https://doi.org/10.1016/j.jpedsurg.2008.08.046
Kuroda, Tatsuo ; Morikawa, Nobuyuki ; Matsuoka, Kentaro ; Fujino, Akihiro ; Honna, Toshiro ; Nakagawa, Atsuko ; Kumagai, Masaaki ; Masaki, Hidekazu ; Saeki, Morihiro. / Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. :: Journal of Pediatric Surgery. 2008 ; 巻 43, 番号 12. pp. 2182-2185.
@article{e0d8ceb200b64f7484739936023109af,
title = "Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma",
abstract = "Purpose: The aim of this study was to study the prognostic significance of circulating tumor cells (CTC) and the appropriate indications for aggressive surgery in advanced neuroblastoma. Materials and Methods: Micrometastasis was sequentially explored using our reverse transcriptase-polymerase chain reaction method in 29 neuroblastoma patients (International Neuroblastoma Staging System stage 4, n = 24; stage 3, n = 5) who treated at our department with the united chemotherapeutic regimen since 1991. Their medical records and detection of CTC and/or the bone marrow micrometastasis were retrospectively reviewed then analyzed statistically. Results: The overall survival rate was 58.6{\%} (17/29). Circulating tumor cells were detected in 55.6{\%} of the stage 4 patients, and all deaths were related to systemic metastases in the CTC-positive patients. The detection of CTC scarcely associated with MYCN amplification. In the patients showing MYCN amplification but no CTC, all deaths were related to local relapse or chemotherapy-associated complications. The survival rate was not significantly different between the patients with and without MYCN amplification (56.8{\%} vs 52.7{\%}). However, it was significantly lower in the patients with CTC and/or persistent bone marrow micrometastasis compared to those without detectable micrometastasis (33.8{\%} vs 87.5{\%}; P < .05). Conclusions: The presence of CTC and/or persistent micrometastasis may indicate a significantly high risk, regardless of MYCN amplification. Patients with MYCN amplification but no micrometastasis would be most benefited by highly intensive surgery.",
keywords = "Circulating tumor cells, Micrometastasis, Neuroblastoma, Prognosis",
author = "Tatsuo Kuroda and Nobuyuki Morikawa and Kentaro Matsuoka and Akihiro Fujino and Toshiro Honna and Atsuko Nakagawa and Masaaki Kumagai and Hidekazu Masaki and Morihiro Saeki",
year = "2008",
month = "12",
doi = "10.1016/j.jpedsurg.2008.08.046",
language = "English",
volume = "43",
pages = "2182--2185",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma

AU - Kuroda, Tatsuo

AU - Morikawa, Nobuyuki

AU - Matsuoka, Kentaro

AU - Fujino, Akihiro

AU - Honna, Toshiro

AU - Nakagawa, Atsuko

AU - Kumagai, Masaaki

AU - Masaki, Hidekazu

AU - Saeki, Morihiro

PY - 2008/12

Y1 - 2008/12

N2 - Purpose: The aim of this study was to study the prognostic significance of circulating tumor cells (CTC) and the appropriate indications for aggressive surgery in advanced neuroblastoma. Materials and Methods: Micrometastasis was sequentially explored using our reverse transcriptase-polymerase chain reaction method in 29 neuroblastoma patients (International Neuroblastoma Staging System stage 4, n = 24; stage 3, n = 5) who treated at our department with the united chemotherapeutic regimen since 1991. Their medical records and detection of CTC and/or the bone marrow micrometastasis were retrospectively reviewed then analyzed statistically. Results: The overall survival rate was 58.6% (17/29). Circulating tumor cells were detected in 55.6% of the stage 4 patients, and all deaths were related to systemic metastases in the CTC-positive patients. The detection of CTC scarcely associated with MYCN amplification. In the patients showing MYCN amplification but no CTC, all deaths were related to local relapse or chemotherapy-associated complications. The survival rate was not significantly different between the patients with and without MYCN amplification (56.8% vs 52.7%). However, it was significantly lower in the patients with CTC and/or persistent bone marrow micrometastasis compared to those without detectable micrometastasis (33.8% vs 87.5%; P < .05). Conclusions: The presence of CTC and/or persistent micrometastasis may indicate a significantly high risk, regardless of MYCN amplification. Patients with MYCN amplification but no micrometastasis would be most benefited by highly intensive surgery.

AB - Purpose: The aim of this study was to study the prognostic significance of circulating tumor cells (CTC) and the appropriate indications for aggressive surgery in advanced neuroblastoma. Materials and Methods: Micrometastasis was sequentially explored using our reverse transcriptase-polymerase chain reaction method in 29 neuroblastoma patients (International Neuroblastoma Staging System stage 4, n = 24; stage 3, n = 5) who treated at our department with the united chemotherapeutic regimen since 1991. Their medical records and detection of CTC and/or the bone marrow micrometastasis were retrospectively reviewed then analyzed statistically. Results: The overall survival rate was 58.6% (17/29). Circulating tumor cells were detected in 55.6% of the stage 4 patients, and all deaths were related to systemic metastases in the CTC-positive patients. The detection of CTC scarcely associated with MYCN amplification. In the patients showing MYCN amplification but no CTC, all deaths were related to local relapse or chemotherapy-associated complications. The survival rate was not significantly different between the patients with and without MYCN amplification (56.8% vs 52.7%). However, it was significantly lower in the patients with CTC and/or persistent bone marrow micrometastasis compared to those without detectable micrometastasis (33.8% vs 87.5%; P < .05). Conclusions: The presence of CTC and/or persistent micrometastasis may indicate a significantly high risk, regardless of MYCN amplification. Patients with MYCN amplification but no micrometastasis would be most benefited by highly intensive surgery.

KW - Circulating tumor cells

KW - Micrometastasis

KW - Neuroblastoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=56449100469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449100469&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2008.08.046

DO - 10.1016/j.jpedsurg.2008.08.046

M3 - Article

C2 - 19040931

AN - SCOPUS:56449100469

VL - 43

SP - 2182

EP - 2185

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 12

ER -